Proliferating Cell Nuclear Antigen in the Era of Oncolytic Virotherapy

• Published in: Viruses Vol. 16; no. 8; p. 1264
• Main Authors: Kwan, Amy, Mcdermott-Brown, India, Muthana, Munitta
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 07.08.2024; MDPI
• Subjects: Animals; Antibodies; Apoptosis; Breast cancer; Cancer; Cancer therapies; Cell cycle; Cell surface; Cytoplasm; DNA biosynthesis; DNA polymerase; DNA repair; DNA Replication; DNA viruses; Enzymes; Health aspects; Herpes simplex; Humans; immune cells; Immunotherapy; Infectivity; Kinases; Leukocytes (neutrophilic); Macrophages; Metabolism; Neoplasms - therapy; Oncolysis; oncolytic virotherapy; Oncolytic Virotherapy - methods; Oncolytic Viruses - physiology; PCNA; Proliferating cell nuclear antigen; Proliferating Cell Nuclear Antigen - metabolism; Proteins; Replication; Review; Roles; Virulence; United Kingdom; immune cells; oncolytic virotherapy; cancer; PCNA
• ISSN: 1999-4915; 1999-4915
• DOI: 10.3390/v16081264

Proliferating cell nuclear antigen (PCNA) is a well-documented accessory protein of DNA repair and replication. It belongs to the sliding clamp family of proteins that encircle DNA and acts as a mobile docking platform for interacting proteins to mount and perform their metabolic tasks. PCNA presence is ubiquitous to all cells, and when located in the nucleus it plays a role in DNA replication and repair, cell cycle control and apoptosis in proliferating cells. It also plays a crucial role in the infectivity of some viruses, such as herpes simplex viruses (HSVs). However, more recently it has been found in the cytoplasm of immune cells such as neutrophils and macrophages where it has been shown to be involved in the development of a pro-inflammatory state. PCNA is also expressed on the surface of certain cancer cells and can play a role in preventing immune cells from killing tumours, as well as being associated with cancer virulence. Given the growing interest in oncolytic viruses (OVs) as a novel cancer therapeutic, this review considers the role of PCNA in healthy, cancerous, and immune cells to gain an understanding of how PCNA targeted therapy and oncolytic virotherapy may interact in the future.